SSRN eLibrary Search Results
JEL Code: L65

105,051 Total downloads
Search Within

Viewing: 1 - 50 of 556 papers

1.

Drugged Out: How Cognitive Bias Hurts Drug Innovation

51 San Diego Law Review 419 (2014)
Number of pages: 90 Posted: 01 Sep 2013 Last Revised: 09 Aug 2014
Accepted Paper Series
Loyola University of Chicago School of Law
Downloads 10,928
2.

The Effects of Service Quality and Word of Mouth on Customer Acquisition, Retention and Usage

Number of pages: 48 Posted: 11 Mar 2007
Working Paper Series
City University of Hong Kong, University of Michigan, Stephen M. Ross School of Business and University of Chicago
Downloads 3,615
3.

Unpatentable Drugs and the Standards of Patentability

Texas Law Review, Vol. 87, pp. 503-570, 2009
Number of pages: 68 Posted: 04 May 2008 Last Revised: 02 Jun 2013
Accepted Paper Series
MIT Sloan
Downloads 1,772
4.

The Great Global Vitamins Cartels

Number of pages: 190 Posted: 28 Feb 2006 Last Revised: 15 May 2008
Working Paper Series
American Antitrust Institute (AAI)
Downloads 1,137
5.

The Doha Round's Public Health Legacy: Strategies for the Production and Diffusion of Patented Medicines Under the Amended TRIPS Provisions

Journal of International Economic Law, Vol. 10, pp. 921-87, 2007, FSU College of Law, Law and Economics Paper No. 07-25, FSU College of Law, Public Law Research Paper No. 287
Number of pages: 68 Posted: 01 Nov 2007 Last Revised: 01 May 2013
Accepted Paper Series
Florida State University - College of Law and Duke University School of Law
Downloads 942
6.

Has the European Commission Become More Severe in Punishing Cartels? Effects of the 2006 Guidelines

Number of pages: 26 Posted: 11 Jan 2011 Last Revised: 27 Jan 2011
Working Paper Series
American Antitrust Institute (AAI)
Downloads 919
7.

The Untold EpiPen Story: How Mylan Hiked Prices by Blocking Rivals

102 Cornell Law Review Online 53 (2017)
Number of pages: 20 Posted: 21 Sep 2016 Last Revised: 01 Feb 2017
Accepted Paper Series
Rutgers Law School and Rutgers University, Newark, Rutgers Law School, Rutgers School of Law, Students
Downloads 906
8.

Pioneering Advantage in Generic Drug Competition

International Journal of Pharmaceutical and Healthcare Marketing 01/2014; 8(2)
Number of pages: 51 Posted: 20 Aug 2006 Last Revised: 05 Sep 2014
Accepted Paper Series
AIG and Cornell University - Samuel Curtis Johnson Graduate School of Management
Downloads 903
9.

Pharmaceutical Development Phases: A Duration Analysis

FTC, Bureau of Economics Working Paper No. 274
Number of pages: 30 Posted: 25 Oct 2004
Working Paper Series
Global Economics Group, LLC, Federal Trade Commission - Bureau of Economics and Moody's Investors Service
Downloads 889
10.

Business Model Innovation in the Pharmaceutical Industry: The Supporting Role of Organizational Design

Number of pages: 32 Posted: 25 Feb 2014
Working Paper Series
Copenhagen Business School - Department of Strategic Management and Globalization and Copenhagen Business School
Downloads 838
11.

Patent Trolling — Why Bio & Pharmaceuticals Are at Risk

17 Stan. Tech. L. Rev. 773, 2014, UC Hastings Research Paper No. 93
Number of pages: 40 Posted: 15 Feb 2014 Last Revised: 03 Apr 2016
Accepted Paper Series
University of California Hastings College of the Law and University of Michigan Law School
Downloads 835
12.

Competition and Regulation Issues in the Pharmaceutical Industry

Org. for Economic Co-operation & Dev., Best Practice Roundtables in Competition Policy No. 32
Number of pages: 401 Posted: 30 Jul 2002
Working Paper Series
Australian Competition and Consumer Commission
Downloads 814
13.

Asymmetric Social Interactions in Physician Prescription Behavior: The Role of Opinion Leaders

Stanford University Graduate School of Business Research Paper No. 1970
Number of pages: 41 Posted: 13 Oct 2006 Last Revised: 30 Jul 2014
Working Paper Series
Stanford University - Graduate School of Business, University of Michigan, Stephen M. Ross School of Business and Rutgers, The State University of New Jersey - Rutgers Business School at Newark & New Brunswick
Downloads 731
14.

Innovation for the 21st Century: Harnessing the Power of Intellectual Property and Antitrust Law

Oxford University Press, 2009
Number of pages: 16 Posted: 27 Mar 2009
Accepted Paper Series
Rutgers Law School
Downloads 728
15.

Counterfeit Drugs: The Good, the Bad and the Ugly

Albany Law Journal of Science and Technology, Vol. 15, 2006
Number of pages: 15 Posted: 30 Aug 2006
Accepted Paper Series
Boston University School of Law and West Virginia University - College of Law
Downloads 704
16.

Cartel Overcharges and Optimal Cartel Fines

Number of pages: 16 Posted: 16 Nov 2007 Last Revised: 20 Nov 2007
Working Paper Series
University of Baltimore - School of Law and American Antitrust Institute (AAI)

Multiple version iconThere are 2 versions of this paper

Downloads 698
17.

Some Accounting and Technical Problems with Antidumping Trade Cases Involving a Transition Economy: A Russian Case Study

Number of pages: 15 Posted: 12 Sep 2003
Working Paper Series
Fayetteville State University - Department of Accounting and Abu Dhabi University - Department of Accounting
Downloads 688
18.

Do National Patent Laws Stimulate Domestic Innovation in a Global Patenting Environment? A Cross-Country Analysis of Pharmaceutical Patent Protection, 1978-2002

Review of Economics and Statistics, Vol. 89, No. 3, 2007
Number of pages: 18 Posted: 28 Oct 2007 Last Revised: 08 Jun 2014
Accepted Paper Series
Downloads 681
19.

Access to Information and the Right to Health: The Human Rights Case for Clinical Trials Transparency

American Journal of Law and Medicine, Vol. 38, pp. 63-112, 2012
Number of pages: 50 Posted: 27 Sep 2011 Last Revised: 06 Mar 2015
Accepted Paper Series
University of Toronto - Faculty of Law and Independent
Downloads 678
20.

Countervailing Power in Wholesale Pharmaceuticals

MIT Dept. of Economics Working Paper No. 01-27
Number of pages: 40 Posted: 25 Jul 2001
Working Paper Series
Massachusetts Institute of Technology (MIT) - Department of Economics and Dartmouth College - Department of Economics
Downloads 662
21.

Heterogeneous Learning and the Targeting of Marketing Communication for New Products

Number of pages: 43 Posted: 12 Oct 2006
Working Paper Series
Stanford Graduate School of Business and University of Michigan, Stephen M. Ross School of Business
Downloads 650
22.

Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health

Journal of Law, Medicine and Ethics, Forthcoming
Number of pages: 30 Posted: 28 Jun 2013 Last Revised: 24 Oct 2015
Accepted Paper Series
Carleton University - School of Public Policy and Administration
Downloads 629
23.

The Size of Cartel Overcharges: Implications for U.S. and E.U. Fining Policies

Number of pages: 40 Posted: 31 May 2007 Last Revised: 17 Sep 2008
Working Paper Series
American Antitrust Institute (AAI) and University of Baltimore - School of Law
Downloads 627
24.

Two Puzzles Resolved: Of the Schumpeter - Arrow Stalemate and Pharmaceutical Innovation Markets

Iowa Law Review, Vol. 93, 2008
Number of pages: 58 Posted: 09 Apr 2007 Last Revised: 02 Jun 2013
Accepted Paper Series
Rutgers Law School
Downloads 627
25.

Pharmaceutical Marketing: Medical and Industry Biases

Journal of Pharmaceutical Finance, Economics & Policy, Forthcoming
Number of pages: 17 Posted: 04 Feb 2004
Accepted Paper Series
Emory University - Department of Economics
Downloads 626
26.

Synthesizing Law for Synthetic Biology

Minnesota Journal of Law, Science & Technology, Vol. 11, No. 2, pp. 629-65, 2010
Number of pages: 37 Posted: 25 Jun 2010
Accepted Paper Series
University of Kansas - School of Law
Downloads 623
27.

A Real-World Analysis of Pharmaceutical Settlements: The Missing Dimension of Product-Hopping

Florida Law Review, Vol. 62, 2010
Number of pages: 28 Posted: 14 Apr 2010 Last Revised: 28 Dec 2013
Working Paper Series
Rutgers Law School
Downloads 601
28.

REACHing Asia Continued

Number of pages: 13 Posted: 18 Sep 2009
Working Paper Series
Ghent University - Faculty of Law
Downloads 594
29.

Effectiveness of Antitrust Sanctions on Modern International Cartels

Journal of Industry, Competition, and Trade 6 (2006): 195-223
Number of pages: 29 Posted: 31 May 2007 Last Revised: 09 Mar 2013
Accepted Paper Series
American Antitrust Institute (AAI)
Downloads 582
30.

Marketing, Product Differentiation and Competition in the Market for Antiulcer Drugs

HBS Working Paper No. 01-014
Number of pages: 49 Posted: 23 Mar 2006
Working Paper Series
Greylock McKinnon Associates
Downloads 581
31.

Consumer Protection in an Era of Globalization

IMPORT SAFETY: REGULATORY GOVERNANCE IN THE GLOBAL ECONOMY, Cary Coglianese, Adam Finkel & David Zaring, eds., University of Pennsylvania Press, 2009 , U of Penn, Inst for Law & Econ Research Paper No. 11-10
Number of pages: 20 Posted: 25 Mar 2011
Accepted Paper Series
University of Pennsylvania Law School, University of Pennsylvania Law School and University of Pennsylvania - Legal Studies Department
Downloads 575
32.

Using Antitrust Law to Challenge Turing's Daraprim Price Increase

31 Berkeley Technology Law Journal 1379 (2017)
Number of pages: 30 Posted: 29 Jan 2016 Last Revised: 14 Jul 2017
Accepted Paper Series
Rutgers Law School, Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics and Brigham and Women's Hospital/Harvard Medical School
Downloads 572
33.

Diversification Strategy in the Pharmaceutical Industry

Number of pages: 20 Posted: 14 Oct 2008
Working Paper Series
"Alexandru Ioan Cuza" University of Iasi, Romania
Downloads 565
34.

The United States Department of Justice Antitrust Division's Cartel Enforcement: Appraisal and Proposals

American Antitrust Institute Working Paper No. 08-02
Number of pages: 93 Posted: 08 May 2008 Last Revised: 22 May 2009
Working Paper Series
American Antitrust Institute (AAI)
Downloads 564
35.

Global Antitrust Prosecutions of International Cartels: Focus on Asia

Number of pages: 34 Posted: 07 Nov 2007 Last Revised: 20 Apr 2009
Working Paper Series
American Antitrust Institute (AAI)
Downloads 557
36.

BiDil: Race Medicine or Race Marketing?

Health Affairs, October 11, 2005
Number of pages: 9 Posted: 26 Oct 2005
Accepted Paper Series
University of Pennsylvania - Perelman School of Medicine and Mitchell Hamline School of Law
Downloads 552
37.

Quantifying the Benefits of Individual Level Targeting in the Presence of Firm Strategic Behavior

Number of pages: 50 Posted: 17 Oct 2006
Working Paper Series
Santa Clara University - Marketing, University of Michigan, Stephen M. Ross School of Business and University of Chicago
Downloads 540
38.

The Indian Pharmaceutical Industry - Fundamentals vis-a-vis Market Perception

Number of pages: 23 Posted: 08 Mar 2009
Working Paper Series
Calcutta Business School and affiliation not provided to SSRN
Downloads 537
39.

What is 'Business Development'? The Case of Biotechnology

Schmalenbach Business Review, Vol. 59, April 2007
Number of pages: 25 Posted: 04 Aug 2007
Accepted Paper Series
affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 533
40.

Do Reverse Payment Settlements Violate the Antitrust Laws?

Santa Clara Computer and High Technology Law Journal, Vol. 23, p. 489, 2007
Number of pages: 99 Posted: 30 May 2007
Accepted Paper Series
University of Missouri - Kansas City School of Law
Downloads 527
41.

Determinants of the Round-to-round Returns to Pre-IPO Venture Capital Investments in U.S. Biotechnology Companies

Number of pages: 44 Posted: 08 Jan 2004
Working Paper Series
University of North Carolina Kenan-Flagler Business School
Downloads 526
42.

Can Compulsory Licensing Improve Access to Essential Medicines?

Number of pages: 21 Posted: 23 Apr 2008
Working Paper Series
University of Connecticut - School of Business
Downloads 518
43.

Regulatory Exposure of Deceptive Marketing and its Impact on Firm Value

Journal of Marketing, 2009
Number of pages: 49 Posted: 11 Sep 2009
Accepted Paper Series
Martha Myslinski Tipton, University of Georgia--Terry School of Business and University of Pennsylvania - Legal Studies Department
Downloads 516
44.

The Economic Sense of Royalty Rates

Number of pages: 5 Posted: 06 Aug 1997
Working Paper Series
Financial-Tip
Downloads 515
45.

Cartel Amnesties Granted: Worldwide Whistleblowers

Number of pages: 26 Posted: 21 Oct 2008
Working Paper Series
American Antitrust Institute (AAI)
Downloads 510
46.

Unsettling Drug Patent Settlements: A Framework for Presumptive Illegality

Michigan Law Review, Vol. 108
Number of pages: 44 Posted: 11 Mar 2009 Last Revised: 05 May 2015
Accepted Paper Series
Rutgers Law School
Downloads 506
47.

Valuation of Intangible Assets: Estimating Late-Stage Development Cost of Pharmaceutical R&D

Number of pages: 52 Posted: 12 Sep 2007
Working Paper Series
Kingston University and Henley Management College - Henley Centre for Value Improvement (HCVI)
Downloads 502
48.

Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry

MIT Department of Economics Working Paper No. 03-33
Number of pages: 59 Posted: 21 Oct 2003
Working Paper Series
Massachusetts Institute of Technology (MIT) - Department of Economics and Massachusetts Institute of Technology (MIT) - Department of Economics

Multiple version iconThere are 2 versions of this paper

Downloads 495
49.

New Drug Development: Estimating Entry from Human Clinical Trials

FTC Bureau of Economics Working Paper No. 262
Number of pages: 24 Posted: 12 Sep 2003
Working Paper Series
Federal Trade Commission - Bureau of Economics and Federal Trade Commission - Bureau of Economics
Downloads 481
50.

A Dynamic Oligopoly Structural Model for the Prescription Drug Market after Patent Expiration

International Economic Review, Vol. 51, No. 4, pp. 1175-1207, November 2010
Number of pages: 57 Posted: 16 Jun 2008 Last Revised: 31 Jul 2012
Accepted Paper Series
University of Toronto - Rotman School of Management

Multiple version iconThere are 2 versions of this paper

Downloads 477